Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jun 21, 2011

Premium

Debra Gordon has been tapped to be vice president and chief legal counsel at HTG Molecular Diagnostics. Prior to joining HTG, Gordon served as general counsel for Ventana Medical Systems.


Corning has hired Richard Eglen to be vice president and general manager of its Corning Life Sciences business segment. Eglen formerly led the Biodiscovery business for PerkinElmer. He takes over the post from Mark Beck, who will now lead Corning's Environmental Technologies segment.


Allegro Diagnostics has appointed Michael Webb to be president and CEO and to serve on its board of directors. Webb previously was president and CEO of Anchor Therapeutics and EPIX Pharmaceuticals. He also is executive chairman of Virtify and he has been chairman of the Massachusetts Biotechnology Council.


Kevin Krenitsky has been named chief operating officer at Foundation Medicine. Krenitsky previously was president of Enzo Clinical Labs. Before his time at Enzo, he was CEO at BioServe Biotechnologies and Parkway Clinical Laboratories.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.